Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome

Journal of Endocrinological Investigation

Volumn 33, Issue 2, 2010, Pages 77-82

  Sun, L ^a   Lv, H ^a   Wei, W ^a   Zhang, D ^a   Guan, Y ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

ACE; Gene polymorphism; PAI 1; Polycystic ovarian syndrome; Spontaneous abortions

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; FOLLITROPIN; GLUCOSE; INSULIN; LUTEINIZING HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TESTOSTERONE;

ADULT; AGE DISTRIBUTION; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; DNA POLYMORPHISM; FEMALE; FOLLITROPIN BLOOD LEVEL; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; LIVE BIRTH; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; OVARY POLYCYSTIC DISEASE; PREGNANCY OUTCOME; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SPONTANEOUS ABORTION; TESTOSTERONE BLOOD LEVEL;

ABORTION, SPONTANEOUS; ADULT; FEMALE; FOLLICLE STIMULATING HORMONE; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; INSULIN; LUTEINIZING HORMONE; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; POLYMORPHISM, GENETIC; PREGNANCY; PROSPECTIVE STUDIES; TESTOSTERONE; WAIST-HIP RATIO;

EID: 77951862740     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/6470     Document Type: Article

References (31)

1. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91: 48-53.
2. Barth JH, Yasmin E, Balen AH. The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research. Clin Endocrinol (Oxf) 2007, 67: 811-815 (Pubitemid 350135121)
3. Franks S, Gharani N, Waterworth D, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997, 12: 2641-2648 (Pubitemid 28031723)
4. Carmina E. Genetic and environmental aspect of polycystic ovary syndrome. J Endocrinol Invest 2003, 26: 1151-1159 (Pubitemid 38195457)
5. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87: 524-529 (Pubitemid 34158214)
6. Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin. Clin Appl Thromb Hemost 2004, 10: 323-334
7. van der Spuy ZM, Dyer SJ. The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004, 18: 755-771 (Pubitemid 40424609)
8. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001, 75: 46-52. (Pubitemid 32041226)
9. Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin, China. Chin Med J (Engl) 2003, 116: 1707-1710
10. Kohler H, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000, 342: 1792-1801 (Pubitemid 30390240)
11. Lockwood CJ. Regulation of plasminogen activator inhibitor 1 expression by interaction of epidermal growth factor with progestin during decidualization of human endometrial stromal cells. Am J Obstet Gynecol 2001, 184: 798-804.
12. Buchholz T, Lohse P, Rogenhofer N, Kosian E, Pihusch R, Thaler CJ. Polymorphisms in the ACE and PAI-1 genes are associated with recurrent spontaneous miscarriages. Hum Reprod 2003, 18: 2473-2477 (Pubitemid 37427834)
13. Kim DK, Kim JW, Kim S, et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997, 17: 3242-3247 (Pubitemid 28016084)
14. Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 1995, 92: 1851-1855
15. Prisco D, Fatini C, Battaglini B, et al. Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients. Int J Clin Lab Res 2000, 30: 179-185 (Pubitemid 32176912)
16. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 2003, 49: 1081-1086 (Pubitemid 36751094)
17. Glueck CJ, Awadalla SG, Phillips H, Cameron D, Wang P, Fontaine RN. Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. Fertil Steril 2000, 74: 394-397 (Pubitemid 30608221)
18. Glueck CJ, Phillips H, Cameron D, et al. The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism 2000, 49: 845-852 (Pubitemid 30483435)
19. Glueck CJ, Wang P, Bornovali S, Goldenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 2003, 52: 1627-1632 (Pubitemid 38049284)
20. Sampson M, Kong C, Patel A, Unwin R, Jacobs HS. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996, 45: 623-629 (Pubitemid 26411365)
21. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81: 19-25.
22. Tsanadis G, Vartholomatos G, Korkontzelos I, et al. Polycystic ovarian syndrome and thrombophilia. Hum Reprod 2002, 17: 314-319 (Pubitemid 34168433)
23. Fatini C, Gensini F, Battaglini B, et al. Angiotensin-Converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagul Fibrinolysis 2000, 11: 657-662
24. Hacihanefioglu B, Somunkiran A, Mahmutoglu I, Sercelik A, Toptani S, Kervancioglu E. Effect of hypertension therapy with the angiotensin-converting enzyme inhibitor lisinopril on hyperandrogenism in women with polycystic ovary syndrome. Fertil Steril 2002, 77: 526-528 (Pubitemid 34177207)
25. Yamada N, Arinami T, Yamakawa-Kobayashi K, et al. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet 2000, 45: 138-141 (Pubitemid 30324115)
26. Fabbro D, D'Elia AV, Spizzo R et al. Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest 2003, 56: 17-22. (Pubitemid 37025942)
27. Glueck CJ, Wang P, Fontaine RN, Sieve Smith L, Tracy T, Moore SK. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999, 48: 1589-1595
28. Zhao JL, Chen ZJ, Zhao YR, et al. Correlation between 4G and 5G genetypes distribution of plasminogen activator inhibitor-1 gene polymorphism in its promoter region with polycystic ovarian syndrome. Zhonghua Fu Chan Ke Za Zhi 2005, 40: 528-531
29. Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006, 55: 345-352 (Pubitemid 43234388)
30. Atiomo WU, Fox R, Condon JE, et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 2000, 52: 487-492
31. Ballian N, Mantoudis E, Kaltsas GA. Pregnancy following ovarian drilling in a woman with polycystic ovary syndrome and nine previous first trimester miscarriages. Arch Gynecol Obstet 2006, 273: 384-386 (Pubitemid 43296583)